RU2317294C2 - (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора - Google Patents
(имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора Download PDFInfo
- Publication number
- RU2317294C2 RU2317294C2 RU2004136979/04A RU2004136979A RU2317294C2 RU 2317294 C2 RU2317294 C2 RU 2317294C2 RU 2004136979/04 A RU2004136979/04 A RU 2004136979/04A RU 2004136979 A RU2004136979 A RU 2004136979A RU 2317294 C2 RU2317294 C2 RU 2317294C2
- Authority
- RU
- Russia
- Prior art keywords
- pyridazine
- ylmethyl
- methylimidazol
- lower alkyl
- fluorophenyl
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title claims abstract 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title claims abstract 4
- GFSWLEBKUPUQNQ-UHFFFAOYSA-N 3-(imidazol-1-ylmethyl)pyridazine Chemical compound C1=CN=CN1CC1=CC=CN=N1 GFSWLEBKUPUQNQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract 10
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 125000005750 substituted cyclic group Chemical group 0.000 claims abstract 2
- -1 3-chloro-4-fluorophenyl Chemical group 0.000 claims 11
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- ITXNRQKPXQBCQT-UHFFFAOYSA-N 5-(1-benzothiophen-5-yl)-3-[(2-methylimidazol-1-yl)methyl]pyridazine Chemical compound CC1=NC=CN1CC1=CC(C=2C=C3C=CSC3=CC=2)=CN=N1 ITXNRQKPXQBCQT-UHFFFAOYSA-N 0.000 claims 1
- ULGGCXZAFZNRQJ-UHFFFAOYSA-N 5-(3,4-dihydronaphthalen-2-yl)-3-[(2-methylimidazol-1-yl)methyl]pyridazine;hydrochloride Chemical compound Cl.CC1=NC=CN1CC1=CC(C=2CCC3=CC=CC=C3C=2)=CN=N1 ULGGCXZAFZNRQJ-UHFFFAOYSA-N 0.000 claims 1
- LRTWVDJKDKWTPA-UHFFFAOYSA-N 5-(3-cyclopropyl-4-fluorophenyl)-3-[(2-methylimidazol-1-yl)methyl]pyridazine Chemical compound CC1=NC=CN1CC1=CC(C=2C=C(C(F)=CC=2)C2CC2)=CN=N1 LRTWVDJKDKWTPA-UHFFFAOYSA-N 0.000 claims 1
- BOVUHBFXPNLTKF-UHFFFAOYSA-N 5-[3-(difluoromethyl)-4-fluorophenyl]-3-[(2-methylimidazol-1-yl)methyl]pyridazine Chemical compound CC1=NC=CN1CC1=CC(C=2C=C(C(F)=CC=2)C(F)F)=CN=N1 BOVUHBFXPNLTKF-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 0 Cc1c[s]c(*)c1 Chemical compound Cc1c[s]c(*)c1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Изобретение относится к новым соединениям формулы I
в которой R означает водород или низший алкил, а А означает незамещенную или замещенную циклическую группу, выбранную из
и где R1-R4 означают, независимо друг от друга, водород, галоген, CF3, CHF2, С(СН3)F2, С3-С6-циклоалкил, низшую алкоксигруппу, низший алкил, OCF3 или фенил; R5-R10 означают, независимо друг от друга, водород, галоген, низшую алкоксигруппу, низший алкил или CHF2; R11-R16 означают, независимо друг от друга, водород, галоген, низшую алкоксигруппу или низший алкил; R17 означает галоген или CHF2; R18-R20 означают, независимо друг от друга, водород, низшую алкоксигруппу или низший алкил; и их фармацевтически приемлемым кислотно-аддитивным солям. Изобретение также относится к лекарственному средству, обладающему селективным действием блокаторов NMDA рецепторов подтипа 2В. Технический результат - получение новых биологически активных соединений и лекарственных средств на их основе. 2 н.и 4 з.п. ф-лы.
Description
Текст описания приведен в факсимильном виде.
Claims (6)
1. Соединения формулы I
в которой R означает водород или низший алкил, а
А означает незамещенную или замещенную циклическую группу, выбранную из
где R1-R4 означают независимо друг от друга водород, галоген, CF3, CHF2, С(СН3)F2, С3-С6-циклоалкил, низшую алкоксигруппу, низший алкил, OCF3 или фенил;
R5-R10 означают независимо друг от друга водород, галоген, низшую алкоксигруппу, низший алкил или CHF2;
R11-R16 означают независимо друг от друга водород, галоген, низшую алкоксигруппу или низший алкил;
R17 означает галоген или CHF2;
R18-R20 означают независимо друг от друга водород, низшую алкоксигруппу или низший алкил,
и их фармацевтически приемлемые кислотно-аддитивные соли.
2. Соединения по п.1, представляющие собой
5-(3-хлор-4-фторфенил)-3-(2-метилимидазол-1-илметил)пиридазин,
3-(2-метилимидазол-1-илметил)-5-(3-трифторметилфенил)пиридазин,
5-(3-дифторметил-4-фторфенил)-3-(2-метилимидазол-1-илметил)пиридазин,
5-[3-(1,1-дифторэтил)фенил]-3-(2-метилимидазол-1-илметил)пиридазин,
5-[3-(1,1-дифторэтил)-4-фторфенил]-3-(2-метилимидазол-1-илметил)пиридазин,
5-(4-фтор-3-метилфенил)-3-(2-метилимидазол-1-илметил)пиридазин,
5-(4-хлор-3-метилфенил)-3-(2-метилимидазол-1-илметил)пиридазин,
5-[3-(1,1-дифторэтил)-5-фторфенил]-3-(2-метилимидазол-1-илметил)пиридазин,
5-(3-дифторметил)-4-фторфенил]-3-(2-этилимидазол-1-илэтил)пиридазин,
5-(3-циклопропил-4-фторфенил)-3-(2-метилимидазол-1-илметил)пиридазин.
3. Соединения по п.1, где соединение представляет собой
5-бензо[b]тиофен-5-ил-3-(2-метилимидазол-1-илметил)пиридазин.
4. Соединения по п.1, где соединение представляет собой
5-(3,4-дигидронафт-2-ил)-3-(2-метилимидазол-1-илметил)пиридазин гидрохлорид.
5. Лекарственное средство, обладающее селективным действием блокаторов NMDA рецепторов подтипа 2В, для лечения заболеваний, содержащее одно или более соединений формулы I по одному из пп.1-4 или их фармацевтически приемлемую соль и инертные носители.
6. Лекарственное средство по п.5 для лечения заболеваний, имеющих терапевтические показания к применению субтипов специфических блокаторов NMDA рецепторов, которые включают острые формы нейродегенерации, вызванной, например, ударом или травмой головного мозга, хронические формы нейродегенерации, такие, как болезнь Альцгеймера, болезнь Паркинсона, болезнь Хантингтона, АЛС (амиотропный латеральный склероз), и нейродегенерацию, вызванную бактериальной или вирусной инфекцией, дискинезию, болезни привыкания, депрессию и хроническую или острую боль.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02010217.4 | 2002-05-16 | ||
| EP02010217 | 2002-05-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004136979A RU2004136979A (ru) | 2005-07-10 |
| RU2317294C2 true RU2317294C2 (ru) | 2008-02-20 |
Family
ID=29433072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004136979/04A RU2317294C2 (ru) | 2002-05-16 | 2003-05-16 | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7005432B2 (ru) |
| EP (1) | EP1506190B1 (ru) |
| JP (1) | JP4267569B2 (ru) |
| KR (1) | KR100632868B1 (ru) |
| CN (1) | CN1312151C (ru) |
| AR (1) | AR040010A1 (ru) |
| AT (1) | ATE329912T1 (ru) |
| AU (1) | AU2003242542B2 (ru) |
| BR (1) | BR0311177A (ru) |
| CA (1) | CA2485926C (ru) |
| CL (1) | CL2004001251A1 (ru) |
| CY (1) | CY1105159T1 (ru) |
| DE (1) | DE60306152T2 (ru) |
| DK (1) | DK1506190T3 (ru) |
| ES (1) | ES2265581T3 (ru) |
| HR (1) | HRP20041060B1 (ru) |
| IL (1) | IL164922A (ru) |
| MA (1) | MA27117A1 (ru) |
| ME (1) | MEP76708A (ru) |
| MX (1) | MXPA04011253A (ru) |
| NO (1) | NO329605B1 (ru) |
| NZ (1) | NZ536310A (ru) |
| PL (1) | PL211340B1 (ru) |
| PT (1) | PT1506190E (ru) |
| RS (1) | RS51200B (ru) |
| RU (1) | RU2317294C2 (ru) |
| SI (1) | SI1506190T1 (ru) |
| TN (1) | TNSN04224A1 (ru) |
| WO (1) | WO2003097637A1 (ru) |
| ZA (1) | ZA200408789B (ru) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| CN100579579C (zh) * | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
| US8674141B2 (en) | 2005-05-03 | 2014-03-18 | Merck Patent Gmbh | Organic electroluminescent device and boric acid and borinic acid derivatives used therein |
| US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| JP5315710B2 (ja) * | 2008-02-07 | 2013-10-16 | セントラル硝子株式会社 | １−ブロモ−３−フルオロ−５−ジフルオロメチルベンゼンの製造方法 |
| DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
| BRPI0909378A2 (pt) * | 2008-03-27 | 2015-10-06 | Evotec Neurosciences Gmbh | métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b |
| ME02337B (me) | 2009-02-05 | 2016-06-20 | Takeda Pharmaceuticals Co | Jedinjenja piridazinona |
| US8883788B2 (en) | 2010-08-04 | 2014-11-11 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| WO2012019106A2 (en) * | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| US9981950B2 (en) * | 2014-08-15 | 2018-05-29 | Janssen Pharmaceuticals, Inc. | Triazoles as NR2B receptor inhibitors |
| DE102015011861B4 (de) | 2015-09-10 | 2018-03-01 | Rudolf Schindler | Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren |
| RS60834B1 (sr) | 2015-12-09 | 2020-10-30 | Cadent Therapeutics Inc | Modulatori heteroaromatskog nmda receptora i njihove upotrebe |
| SG11201806750WA (en) | 2016-02-10 | 2018-09-27 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
| MX2018009857A (es) | 2016-02-18 | 2018-11-09 | Syngenta Participations Ag | Derivados de pirazol pesticidicamente activos. |
| WO2017158151A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| WO2017158147A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| EP3558318B1 (en) | 2016-12-22 | 2023-12-20 | Novartis AG | Nmda receptor modulators and uses thereof |
| EP3774732A4 (en) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| EP4223760B1 (en) | 2018-08-03 | 2025-06-04 | Novartis AG | Heteroaromatic nmda receptor modulator and uses thereof |
| CN113993583A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途 |
| US11459336B2 (en) | 2019-06-14 | 2022-10-04 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| US11618750B2 (en) | 2019-06-14 | 2023-04-04 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators |
| PH12021552839A1 (en) | 2019-06-14 | 2022-10-03 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
| BR112021024117A2 (pt) | 2019-06-14 | 2022-03-22 | Janssen Pharmaceutica Nv | Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b |
| CN114478210A (zh) * | 2022-02-26 | 2022-05-13 | 江苏壹药新材料有限公司 | 一种7-氯萘-2-甲醛的合成方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2060255C1 (ru) * | 1990-04-04 | 1996-05-20 | Хехст АГ | Способ получения производных имидазола или их физиологически переносимых солей |
| EP0937458A2 (en) * | 1998-02-10 | 1999-08-25 | F. Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives |
| US5962472A (en) * | 1996-03-08 | 1999-10-05 | Hoffmann-La Roche Inc. | Use of 4-phenyl-3,6-dihydro-2H-pyridyl derivatives |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| US6359138B1 (en) * | 1996-12-03 | 2002-03-19 | Hoffmann-La Roche Inc. | 4-hydroxy-piperidine derivatives |
| WO2002028814A2 (en) * | 2000-10-06 | 2002-04-11 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI254043B (en) * | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
| ATE257827T1 (de) * | 1999-07-21 | 2004-01-15 | Hoffmann La Roche | Triazolderivate |
| CA2404464C (en) * | 2000-04-20 | 2008-03-11 | F. Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders |
| US6432985B2 (en) * | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| CA2381630A1 (en) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
| DE10120159A1 (de) | 2001-04-25 | 2002-10-31 | Merck Patent Gmbh | NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
-
2003
- 2003-05-09 US US10/434,955 patent/US7005432B2/en not_active Expired - Fee Related
- 2003-05-15 AR ARP030101685A patent/AR040010A1/es active IP Right Grant
- 2003-05-16 ES ES03752750T patent/ES2265581T3/es not_active Expired - Lifetime
- 2003-05-16 CA CA002485926A patent/CA2485926C/en not_active Expired - Fee Related
- 2003-05-16 AU AU2003242542A patent/AU2003242542B2/en not_active Ceased
- 2003-05-16 RS YUP-985/04A patent/RS51200B/sr unknown
- 2003-05-16 NZ NZ536310A patent/NZ536310A/en not_active IP Right Cessation
- 2003-05-16 EP EP03752750A patent/EP1506190B1/en not_active Expired - Lifetime
- 2003-05-16 PL PL374224A patent/PL211340B1/pl unknown
- 2003-05-16 WO PCT/EP2003/005151 patent/WO2003097637A1/en not_active Ceased
- 2003-05-16 DE DE60306152T patent/DE60306152T2/de not_active Expired - Lifetime
- 2003-05-16 MX MXPA04011253A patent/MXPA04011253A/es active IP Right Grant
- 2003-05-16 ME MEP-767/08A patent/MEP76708A/xx unknown
- 2003-05-16 AT AT03752750T patent/ATE329912T1/de active
- 2003-05-16 CN CNB038111926A patent/CN1312151C/zh not_active Expired - Fee Related
- 2003-05-16 BR BR0311177-6A patent/BR0311177A/pt not_active IP Right Cessation
- 2003-05-16 DK DK03752750T patent/DK1506190T3/da active
- 2003-05-16 RU RU2004136979/04A patent/RU2317294C2/ru not_active IP Right Cessation
- 2003-05-16 HR HR20041060 patent/HRP20041060B1/xx not_active IP Right Cessation
- 2003-05-16 PT PT03752750T patent/PT1506190E/pt unknown
- 2003-05-16 JP JP2004505370A patent/JP4267569B2/ja not_active Expired - Fee Related
- 2003-05-16 KR KR1020047018485A patent/KR100632868B1/ko not_active Expired - Fee Related
- 2003-05-16 SI SI200330332T patent/SI1506190T1/sl unknown
-
2004
- 2004-05-24 CL CL200401251A patent/CL2004001251A1/es unknown
- 2004-10-28 IL IL164922A patent/IL164922A/en not_active IP Right Cessation
- 2004-10-28 NO NO20044666A patent/NO329605B1/no not_active IP Right Cessation
- 2004-10-29 ZA ZA2004/08789A patent/ZA200408789B/en unknown
- 2004-11-11 TN TNP2004000224A patent/TNSN04224A1/fr unknown
- 2004-11-12 MA MA27943A patent/MA27117A1/fr unknown
-
2006
- 2006-08-22 CY CY20061101161T patent/CY1105159T1/el unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2060255C1 (ru) * | 1990-04-04 | 1996-05-20 | Хехст АГ | Способ получения производных имидазола или их физиологически переносимых солей |
| US5962472A (en) * | 1996-03-08 | 1999-10-05 | Hoffmann-La Roche Inc. | Use of 4-phenyl-3,6-dihydro-2H-pyridyl derivatives |
| US6359138B1 (en) * | 1996-12-03 | 2002-03-19 | Hoffmann-La Roche Inc. | 4-hydroxy-piperidine derivatives |
| EP0937458A2 (en) * | 1998-02-10 | 1999-08-25 | F. Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| WO2002028814A2 (en) * | 2000-10-06 | 2002-04-11 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| RU2219167C2 (ru) | N-замещенные аминотетралины как лиганды для рецептора y5 нейропептида y, полезные при лечении ожирения и других расстройств | |
| RU2320657C2 (ru) | Новые производные пирролидиния | |
| RU2218335C2 (ru) | Производные фенил- и аминофенилалкилсульфонамида и фармацевтическая композиция на их основе | |
| RU2332212C2 (ru) | Аминоспирт | |
| RU2312106C2 (ru) | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar | |
| JP2011511840A5 (ru) | ||
| KR930023340A (ko) | 아릴아세트아미드 | |
| JP2007538024A5 (ru) | ||
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| RU2009136592A (ru) | Терапевтические агенты | |
| JP2007507494A5 (ru) | ||
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| RU2010134411A (ru) | Фенилацетамидное производное | |
| RU2219179C2 (ru) | Азациклические соединения, фармацевтические композиции | |
| RU95117068A (ru) | Антигипертриглицеридемическая композиция, способ ее получения, способ лечения или профилактики гипертриглицеридемии, применение соединений | |
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| RU2011117927A (ru) | Карбаматное соединение или его соль | |
| RU2314809C2 (ru) | Способ лечения депрессии соединениями-агонистами дельта-рецепторов | |
| RU2221788C2 (ru) | Оксоциклические соединения мочевины, фармацевтическая композиция, способ лечения | |
| RU2007116987A (ru) | Новые соединения | |
| JP2005513017A5 (ru) | ||
| RU2003130644A (ru) | Производные ркарболина и их фармацевтическое применение против дипрессии и страха | |
| JP2004525178A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20131003 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150517 |